Eosinophils are multifunctional leukocytes implicated in the pathogenesis of a wide variety of disorders, including asthma, helminth infections, hematologic malignancies, and hypereosinophilic syndromes (HESs). 1 Although glucocorticoids are first-line therapy for many of these disorders, long-term toxicity is common, and resistance can occur. Whereas clinical trials of novel therapeutic agents targeting eosinophils, including mAbs to IL-5 (mepolizumab and reslizumab) and IL-5 receptor (IL-5R) a (benralizumab), 2, 3 have demonstrated the safety of eosinophil depletion in the treatment of various eosinophilic disorders, including eosinophilic asthma, eosinophilic esophagitis, HES, and eosinophilic granulomatosis with polyangiitis, none has shown complete elimination of tissue eosinophils or clinical symptoms. Clearly, additional targeted therapies are needed.
Human epidermal growth factor (EGF)-like module containing mucin-like hormone receptor 1 (EMR1) is a surface receptor of unknown function that belongs to the EGF-7-transmembrane family of G protein-coupled receptors. 4 Other family members include EMR2 and CD97, molecules involved in modulation of neutrophil activation and leukocyte migration to sites of inflammation. [5] [6] [7] The human ortholog of F4/80, which is expressed on murine monocytes, macrophages, myeloid dendritic cells, and eosinophils, 8 human EMR1 has been reported to be expressed exclusively on eosinophils 9 and to be highly expressed in nasal polyps. 10 Therefore EMR1 is an ideal potential target for the treatment of eosinophilic disorders.
In the present study we describe the expression profile of EMR1 in the blood, bone marrow, and tissue of healthy donors and subjects with a variety of eosinophilic disorders. Modulation of the receptor was also explored ex vivo and in vitro. Finally, the efficacy of an afucosylated chimeric antibody to EMR1 to target eosinophils for natural killer (NK) cell-mediated antibody-dependent cell lysis was assessed in vitro and in vivo in a primate model.
METHODS

Anti-EMR1 mAbs
Recombinant extracellular domains from human and cynomolgus monkey EMR1 were expressed as Fc fusion proteins in Chinese hamster ovary (CHO) cells. After purification on protein A columns, Fc tags were proteolytically removed by using Factor Xa, and human EMR1 extracellular domain was used for immunization in mice. The mouse hybridoma line 1E7, which expresses high-affinity anti-EMR1 mAb, was grown in Hybridoma SFM media (Invitrogen, Carlsbad, Calif). Afucosylated and fucosylated chimeric 1E7 antibodies with human IgG 1 k constant regions were expressed in Potelligent CHOK1SV (Biowa/Lonza, Basel, Switzerland). 11 Murine and chimeric 1E7 antibodies were purified by means of protein A affinity chromatography.
Study subjects
Eosinophilic subjects (n 5 38) underwent detailed clinical and laboratory evaluation as part of an institutional review board-approved clinical protocol to study eosinophilia (NCT00001406) and included subjects with idiopathic HES (n 5 18), lymphocytic variant HES (n 5 7), helminth infection (n 5 4), hypereosinophilia of unknown significance (n 5 3), platelet-derived growth factor receptor A (PDGFRA)-associated myeloproliferative neoplasm (n 5 3), and familial eosinophilia (n 5 2). Six subjects were receiving therapy at the time of study but had persistent eosinophilia (geometric mean [GM] absolute eosinophil count [AEC], 2,167/mL; range, 910-13,000/mL). Healthy volunteers were recruited under an institutional review board-approved clinical protocol designed to obtain control subjects for in vitro research (NCT00090662). All participants provided written informed consent.
Cell purification
Granulocytes and PBMCs were separated by means of sedimentation over Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). Erythrocytes were lysed by means of hypotonic shock with ice-cold ddH 2 O (for granulocytes) or ACK lysing buffer (Quality Biological, Inc, Gaithersburg, Md) (for PBMCs). Individual cell populations were purified by using magnetic bead selection on an AutoMacs (Miltenyi Biotech, Cambridge, Mass), according to the manufacturer's instructions. Eosinophils and neutrophils were purified from the granulocyte layer by using the Eosinophil Isolation Kit (Miltenyi Biotech). NK cells, CD14
1 monocytes, and CD34 1 stem cells were purified from the PBMC layer by using the NK Cell Isolation Kit, anti-CD14 beads, and anti-CD34 beads, respectively (Miltenyi Biotech). Granulocyte purity was determined by counting a minimum of 300 cells on cytospin preparations stained with Diff-Quik (Siemens Healthcare Diagnostics, Malvern, Pa). The purity of other cells was determined by means of flow cytometry. Purity was greater than 98% for all cell populations studied. Cells for RNA expression analysis were counted and put directly in TriZol Reagent (Invitrogen) at a concentration of 10 3 10 6 /mL.
Human cell lines and culture conditions
Purified peripheral blood eosinophils were cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS (BioWhittaker, Walkersville, Md), 25 mmol/L HEPES, 2 mmol/L L-glutamine, 10 mmol/L sodium pyruvate, and 50 mg/mL gentamicin (culture medium). The leukemic cell line EOL1 (DSMZ Institute, Braunschweig, Germany), the erythroleukemia cell line K562 (ATCC CCL-243; ATCC, Manassas, Va), and the histiocytic lymphoma cell line U937 (ATCC CRL-1593.2) were maintained in RPMI 1640 medium with 10% FCS at 378C. AML14.3D10 (ATCC CRL-12079) was maintained in culture medium containing 50 mmol/L b-mercaptoethanol. CHO cells transfected with EMR1 (CHOK1SV) were cultured in CD-CHO (Invitrogen) supplemented with 25 mmol/L L-methionine sulfoximine.
Detection of surface EMR1 by means of flow cytometry
EMR1 expression in bone marrow aspirates and peripheral blood was assessed by using multiparameter flow cytometry with directly conjugated antibodies, as previously described (see the Methods section in this article's Online Repository at www.jacionline.org for detailed methodology). 12 
Real-time quantitative PCR
Total RNA was extracted from purified cell populations and cell lines with TriZol Reagent (Invitrogen), and cDNAwas synthesized from 1 mg of total RNA by using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, Calif), according to the manufacturer's protocol. cDNA from human CD34 1 cells cultured under conditions to induce mast cell differentiation 13 and from the mast cell lines HMC-1.1 (lacking KIT D816V), HMC-1.2 (expressing KIT D816V), and LAD2 were provided by Dr Todd Wilson (National Institute of Allergy and Infectious Diseases/National Institutes of Health [NIH] ). Approximately 50 ng of RNA equivalent cDNA template was used per well, and real-time amplification was performed in a 96-well plate by using a GeneAmp 7900HT Sequence Detection System (Applied Biosystems). Primers used are provided in the Methods section in this article's Online Repository. Each sample was run in triplicate, and cycle threshold values were normalized by using 18S cycle threshold values from corresponding samples.
CD34
1 cell differentiation in vitro 
Tissue immunostaining
A 5-mm skin punch biopsy specimen obtained from a patient with HES was bisected. One half of the specimen was fixed in neutral buffered formalin, routinely processed, sectioned, and stained with hematoxylin and eosin per standard procedures of the Laboratory of Pathology, National Cancer Institute. Immunohistochemical staining for eosinophil peroxidase (EPX) was performed with a mouse anti-mouse mAb (1:500, provided by Dr J. J. Lee). The second portion was snap-frozen for immunostaining with anti-EMR1 antibody (c1E7) by using standard techniques (see the Methods section in this article's Online Repository for detailed methodology).
Acetone-fixed nasal polyp frozen tissue section slides obtained from Capital Biosciences (female patient, chronic rhinosinusitis with nasal polyps and bronchial asthma, 39 years old) were stained with mouse 1E7-Alexa595 (0.6 mg/mL), mouse anti-EPX antibody (diluted 1:200 with 2% BSA with PBS; Abcam, Cambridge, United Kingdom), and/or mouse anti-CD68 (clone KP-1, diluted 1:2; Ventana, Tucson, Ariz) by using standard techniques for visualization by means of immunofluorescence microscopy (see the Methods section in this article's Online Repository for detailed methodology).
Measurement of soluble receptors in plasma
Plasma levels of soluble EMR1 (sEMR1) were measured by using a sandwich ELISA (MyBioSource, San Diego, Calif). All assays were performed in singlicate, and values were calculated on the basis of a standard curve. The minimal detectable concentration of sEMR1 in plasma was 10 pg/mL.
In vitro killing assay
Purified eosinophils (8 3 10 4 target) were incubated with autologous NK cells (effector) at an effector/target ratio of 5:1 in 96-well U-bottom plates at 378C in the presence or absence of 10 mg/mL afucosylated c1E7 or IgG 1 isotype control antibodies. After 4 hours, the assay was stopped by putting the plates on ice and replacing the culture medium with binding buffer (100 mL per well; BD Biosciences, San Jose, Calif). Annexin V-fluorescein isothiocyanate (BD Biosciences) was added, and after 15 minutes of incubation at room temperature, samples were acquired and analyzed on a flow cytometer (LSRII, BD Biosciences). Eosinophils were identified based on their granularity (high side scatter). Antibody-dependent cell-mediated cytotoxicity (ADCC) was determined by gating on Annexin V 1 target cells.
Administration of anti-EMR1 antibody in nonhuman primates
Male cynomolgus macaques received a single intravenous infusion of c1E7 at either 1 mg/kg (n 5 2) or 5 mg/kg (n 5 2) at Bio-Quant (San Diego, Calif) under a protocol approved by Bio-Quant's Institutional Animal Care and Utilization Committee and the attending veterinarian. Whole blood was collected for pharmacokinetic analysis and eosinophil counts at baseline; 5 minutes; 2, 4, and 8 hours; and 1, 2, 4, 8, 15, 22, and 28 days after dosing. The plasma concentration of c1E7 was measured by using a quantitative antigen-based ELISA (see the Methods section in this article's Online Repository for detailed methods). Complete blood counts and serum chemistries were performed before dosing and on days 8, 28, 42, and 56.
Statistical analysis
Statistical analyses were performed with the nonparametric Mann-Whitney U and Wilcoxon tests for unpaired and paired comparisons of group means, respectively, and the Spearman rank test was used for correlation. A P value of less than .05 was considered significant for all analyses. Pharmacokinetic analysis was performed by using a noncompartmental model (see the Methods section in this article's Online Repository).
RESULTS
Surface expression of EMR1 in human subjects is restricted to eosinophils
Flow cytometric analysis was performed with whole blood and bone marrow aspirates from healthy donors and eosinophilic subjects with mAb 1E7 generated against the recombinant EMR1 extracellular domain to confirm that EMR1 expression in human blood and bone marrow is restricted to eosinophils. As reported previously, by using a different anti-EMR1 mAb, 9 EMR1 expression was detected exclusively on eosinophils (CD16 2 CD9
1 granulocytes in blood and IL-5Ra 1
CD16
2 Siglec-8 1 granulocytes in bone marrow aspirates) in all subjects tested (Fig 1,  A-D) . EMR1 1 cells were also positive for IL-5Ra, Siglec-8, CD9, CD15, CD45, and CD49d and negative for CD3, CD14, CD16, CD19, CD34, CD64, and CD203 (data not shown). EMR1 was not detected on mast cells, basophils, monocytes, neutrophils, lymphocytes, the monocytic cell line U937, the erythroleukemic cell line K562, or either of 2 eosinophilic leukemia cell lines, Eol-1 and AMLD14.3D10 (Fig 1, E) , whereas the positive control CHOK1SV cell line (transfected with full-length EMR1 gene) showed uniformly high expression of EMR1 (Fig 1, E) .
Quantitative reverse transcriptase PCR confirmed the presence of EMR1 mRNA in eosinophils from eosinophilic subjects and healthy control subjects (Table I ). EMR1 mRNA expression was not detectable in purified PBMCs, monocytes, or neutrophils; CD34 1 cells isolated from peripheral blood; mast cells generated by means of in vitro differentiation of CD34 1 cells (data not shown); or any of the human cell lines tested (Table I) . 
EMR1 is expressed late in eosinophil development
CD34
1 cells was identified, EMR1 expression was not detected on CD34
1 cells in any of the samples studied (Fig 2, A and B) . Purified peripheral blood CD34 1 cells from 2 donors were differentiated in vitro under conditions known to promote eosinophil development to assess the kinetics of EMR1 expression during eosinophilopoiesis. By day 12 after the addition of IL-5, surface expression of CD34 was no longer detected by using flow cytometry (Fig 2, C) , and approximately 20% of the cells were mature eosinophils (Fast Green-positive; Fig 2, D) . As previously described, 14, 15 expression of mRNA for eosinophil granule proteins and IL-5RA increased during the culture period, beginning approximately 3 to 4 days after addition of IL-5 and peaking at 10 days (Fig 2, F and G) . Surface expression of EMR1 increased steadily, beginning at approximately 8 days after addition of IL-5 (Fig 2, E , and see Fig E1 , B, in this article's Online Repository at www.jacionline.org), and double-staining confirmed that EMR1 1 cells were also positive for IL-5Ra and Siglec-8, which is consistent with an eosinophil phenotype (see Fig E1, C) . EMR1 mRNA expression was first detected at day 4 and slowly increased throughout the culture period (Fig 2, G) .
EMR1 is expressed on tissue eosinophils
Because the pathogenesis of eosinophilic disorders is primarily due to tissue infiltration by eosinophils, EMR1 expression on eosinophils in skin and nasal polyp tissue was examined by using immunostaining. A formalin-fixed skin biopsy specimen from a subject with HES showed scattered eosinophils (Fig 3, A) , with J ALLERGY CLIN IMMUNOL VOLUME 133, NUMBER 5 evidence of degranulation demonstrated on immunostaining with anti-EPX antibody (Fig 3, C) . Anti-EMR1 antibody staining of an adjacent frozen section identified scattered cells in a pattern consistent with intact eosinophils (Fig 3, B) . Immunofluorescence staining of nasal polyp tissue showed colocalization of cells staining positively with anti-EMR1 with EPX 1 eosinophils (Fig 3, D-F) but not CD68 1 macrophages (Fig 3, G-I ).
EMR1 expression is correlated with eosinophilia
Eosinophil surface expression of EMR1 was quantified in whole blood from healthy donors (n 5 16), eosinophilic subjects receiving no treatment (n 5 14), and treated subjects with persistent eosinophilia (n 5 7). Although EMR1 was highly expressed on eosinophils from all subjects, the GM change in mean fluorescence intensity was significantly increased in the healthy donors (5645; 95% CI, 4006-7956) compared with that seen in either the untreated (2832; 95% CI, 1786-4489) or treated (2393; 95% CI, 1248-4587) subjects with eosinophilia (P < .05; Fig 4, A) . Furthermore, AEC was negatively correlated with surface expression of EMR1 (r 5 20.46, P < .001; Fig 4, B) , suggesting that modulation of EMR1 expression occurs in vivo. To further explore this possibility, surface expression of EMR1 and CD69, an early activation marker, was assessed in vitro on purified eosinophils from 8 eosinophilic subjects and 6 healthy donors after incubation for 2 hours in the presence or absence of IL-5 (1 ng/mL). Whereas CD69 expression was upregulated in response to IL-5 in all subjects, expression of EMR1 decreased in 6 of 6 eosinophilic and 4 of 6 healthy subjects, and GM change in mean fluorescence intensity for EMR1 showed a significant, although small, decrease from 3845 to 3475 (P < .05; see Fig  E2, A and B, in this article's Online Repository at www. jacionline.org).
Levels of sEMR1 were assessed by using ELISA in undiluted plasma from 13 eosinophilic and 9 healthy control subjects. sEMR1 was detectable in 15 (68%) of the subjects tested, and levels were positively correlated with AECs (r 5 0.69, P < .001; Fig 1, C) . sEMR1 was not detected in culture supernatants of IL-5-activated eosinophils (n 5 5, data not shown).
EMR1 mRNA levels were positively correlated with AECs (r 5 0.36, n 5 39, P <.05; Fig 4, D) and were significantly increased in eosinophilic donors compared with healthy donors (P < .05, data not shown). In vitro stimulation of purified eosinophils with IL-5 at 1 ng/mL overnight or for 6 hours also induced upregulation of EMR1 transcription, with GM mRNA levels increasing from 4.4 to 9.7 arbitrary units (3 10 25 ) related to 18S rRNA (n 5 13, P < .01; see Fig E2, C) .
Eosinophil killing is enhanced in the presence of afucosylated anti-EMR1 antibody Human IgG 1 lacking the monosaccharide fucose in its carbohydrate moiety has been shown to have enhanced ADCC activity because of increased binding affinity for human FcgRIIIa (Fig 1, A) and blood (Fig 1, B ) from a subject with HES. FITC, Fluorescein isothiocyanate; FSC, forward scatter; PE, phycoerythrin; SSC, side scatter. C-E, Absence of EMR1 expression on cells other than eosinophils in bone marrow (Fig 1, C) and peripheral blood (Fig 1, D) and in cell lines (Fig 1, E) . The CHOK1SV cell line (CHO cells transfected with EMR1) is shown as a positive control. (Fig 2, A) and on purified CD34 1 cells isolated from peripheral blood (Fig 2, B) . FITC, Fluorescein isothiocyanate; PE, phycoerythrin;
SSC, side scatter. C and D, In vitro differentiation of CD34 1 cells. Fast Green/Neutral Red staining of cultured CD34 1 cells 2 days before (Fig 2, C) and 21 days after (Fig 2, D) the addition of IL-5 is shown. The arrow indicates a mature eosinophil with bilobed red nucleus and green secondary granules. E, Surface expression of EMR1 and CD34 as a function of time. Dmfi, Change in mean fluorescence intensity. F and G, mRNA expression as a function of time for EPX, MBP, and EDN (Fig 2, F, left axis) ; ECP (Fig 2, F, right axis) ; EMR1 and Siglec-8 (Fig 2, G, left axis) ; and IL-5RA (Fig 2, G, right axis) .
J ALLERGY CLIN IMMUNOL VOLUME 133, NUMBER 5 receptor. 11 Consequently, an afucosylated chimeric anti-EMR1 mAb (c1E7) was generated and tested in an in vitro NK cell-mediated killing assay by using purified eosinophils as target cells from 4 healthy and 2 eosinophilic human donors (Fig 5, A , and see Fig (Fig 3, A) is shown. Adjacent paraffin-embedded sections stained with antibody to EPX (Fig 3, B) and hematoxylin and eosin (Fig 3, C) showing eosinophilic infiltration and degranulation are also presented. The arrows indicate representative eosinophils (Fig 3, C) . Fig 3, A and B, Original magnification 3600 and 3100 (Fig 3, C) . D-I, Nasal polyp biopsy specimen. Immunofluorescence staining of EMR1 in red (Fig 3, D and G) , EPX (Fig 3, E) or CD68 (Fig 3, H) in green, and an overlay (Fig 3, F and  I) showing EMR1 staining on eosinophils and not on macrophages is shown. Original magnification 3640. increased from 15.1% to 62.3% in the presence of afucosylated c1E7 (P < .05) but not in the presence of antibody isotype control (Fig 5, A) or fucosylated c1E7 antibody at concentrations up to 10 mg/mL (data not shown). Afucosylated c1E7 had no effect on the viability of eosinophils or NK cells when incubated with these cells separately (Fig 5, B) .
Eosinophils are depleted in vivo after a single dose of afucosylated c1E7 antibody
The chimeric antibody c1E7 binds with similar affinity to recombinant human or cynomolgus macaque EMR1, as determined by using ELISA (data not shown). The antibody was administered intravenously to cynomolgus monkeys at a dose of 1 mg/kg (group 1, n 5 2) or 5 mg/kg (group 2, n 5 2). Mean peak plasma concentrations of c1E7 were 41.1 mg/mL for group 1 and 146.7 mg/mL for group 2. The plasma concentration of c1E7 showed a biexponential elimination profile and a terminal phase in all animals, with a mean elimination-phase half-life of 89 hours for group 1 and 210 hours for group 2. Mean volume of distribution of central compartment and volume of distribution at steady state values for each group approximated blood volume consistent with limited tissue distribution (see Table E1 in this article's Online Repository at www.jacionline.org).
Prior studies in cynomolgus monkeys have demonstrated little variability in AECs over time in the absence of treatment. 16, 17 In contrast, peripheral blood eosinophils decreased after infusion in all 4 animals, becoming undetectable at the first time point measured (8 hours) in group 1 and at 2 hours after infusion in group 2 (Fig 6 and see Table E2 in this article's Online Repository at www.jacionline.org). Eosinophil counts returned to normal by day 28 after infusion in the group 1 animals but remained less than baseline counts for 28 to 56 days in the 2 animals that received the 5 mg/kg dose (Fig 6) . A mild rebound eosinophilia was noted in 3 of the 4 animals at day 42, resolving by day 56 in the one animal (CYN 10-65c) for which data are available (Fig 6 and see Table E2 ). The total leukocyte counts excluding eosinophils remained stable after treatment, and no clinically significant adverse events were reported after antibody administration.
Plasma levels of eosinophil granule proteins (major basic protein [MBP], eosinophil cationic protein [ECP], eosinophil-derived neurotoxin [EDN]
, and EPX) were measured at each of the time points by using a suspension array assay in multiplex (see the Methods section in this article's Online Repository) and showed no consistent trend in the first 24 hours after infusion but decreased in all 4 animals over the 28 days after infusion (see Fig E4 in this article' s Online Repository at www.jacionline. org). Additional pharmacokinetic and safety data can be found in Tables E1 and E3 in this article's Online Repository at www. jacionline.org.
DISCUSSION
In their recent report the NIH Taskforce on the Research Needs of Eosinophil-associated Diseases listed the development of new eosinophil-targeted therapeutics as a research priority. 18 In this regard the present study not only confirms previously published data demonstrating that EMR1 expression is restricted to eosinophils 9 but expands this finding to eosinophils from patients with a wide variety of eosinophilic disorders and provides the first evidence that an afucosylated mAb directed against EMR1 can selectively target and safely eliminate eosinophils in vivo in a primate model. Benralizumab (MedImmune, Gaithersburg, Md), an afucosylated antibody against IL-5Ra, has already been used in a phase I trial in patients with mild asthma, demonstrating that enhanced ADCC can be used to deplete eosinophils in human subjects. 17, 19 Although no severe adverse events were reported, none of the subjects in this study had marked eosinophilia (>1500/mL) at baseline.
A major limitation of targeted therapies currently in clinical trials for eosinophilic disorders has been incomplete depletion of tissue eosinophils. At least in part, this is likely due to alterations in eosinophil surface receptor expression that occur during tissue migration and activation. 3 In the present study EMR1 was detected on tissue eosinophils in skin from a patient with HES, nasal polyps, and asthmatic lung disease (data not shown). Of note, EPX staining in the same tissues detected both intact eosinophils and free granules, which is consistent with eosinophil activation. Together these data suggest that EMR1 expression is preserved in activated tissue eosinophils. Nevertheless, the extent to which afucosylated antibody to EMR1 will deplete these tissue eosinophils awaits further study.
EMR1 offers several advantages as a potential therapeutic target. Unlike many eosinophil surface receptors, including IL-5Ra, EMR1 is not expressed on mast cells or basophils, precluding unanticipated adverse effects caused by mediator release during cytolysis of these cells. Similar to 20 EMR1 is expressed relatively late in eosinophil development and is unlikely to deplete CD34 1 eosinophil precursors, which play a potentially important role in plasma cell homeostasis. 21, 22 Finally, although the function of EMR1 is unknown, cynomolgus monkeys experienced no clinically significant adverse effects after administration of anti-EMR1 antibody, and mice deficient in F4/80 (the murine homolog of EMR1) are healthy and fertile. 23 Modulation of cell-surface receptors can occur through a number of different mechanisms, including receptor internalization, proteolytic cleavage, and decreased transcription of mRNA for the membrane form of the receptor. The observed correlation of the peripheral eosinophil count with decreased surface expression of EMR1 on eosinophils and increased plasma levels of sEMR1 supports the hypothesis that EMR1 is shed in vivo in response to signals that promote eosinophilia. The fact that soluble receptor was not detected in culture supernatants despite downmodulation of surface receptor by IL-5 is most likely due to technical constraints related to the concentration of eosinophils in culture, the small change in surface expression in response to IL-5, and the sensitivity of the EMR1 ELISA. Similar findings have been reported for the EGF-7-transmembrane family member CD97, in which increased expression of CD97 in the synovium was accompanied by detectable soluble CD97 in the synovial fluid in subjects with rheumatoid arthritis but not in normal serum or activated T-cell supernatants. 24, 25 Although the mechanism of receptor shedding was not addressed in this study, autoproteolysis of CD97 and EMR2 has been demonstrated to occur through G protein-coupled receptor proteolytic sites in their extracellular domains.
26 EMR1 also contains a G protein-coupled receptor proteolytic site; however, the sequence is imperfect, and functionality of the EMR1 domain has not been demonstrated to date. 27 Although decreased surface receptor and increased soluble receptor levels could both theoretically interfere with the efficacy of a therapeutic antibody to EMR1 in patients with marked eosinophilia, this is unlikely for the following reasons. First, despite the small but significant decrease with increasing AECs, eosinophil surface expression of EMR1 remained high in all subjects tested. Second, in vitro killing was equally efficient in subjects with and without eosinophilia. Third, plasma levels of soluble receptor (10-126 pg/mL; equivalent to approximately 0.1-1.5 pmol/L) were several logs lower than the levels of chimeric afucosylated antibody (2.15 mg/mL [or 14.3 nmol/L] after 15 days and 11.1 mg/mL [or 74 nmol/L] after 28 days for doses at 1 and 5 mg/kg, respectively) achieved in pharmacokinetic studies in nonhuman primates (see Table E3 ).
In summary, EMR1 is expressed exclusively on mature eosinophils in the blood, bone marrow, and tissues of patients with eosinophilia, regardless of the underlying disorder. Although receptor expression is decreased on peripheral blood eosinophils in the setting of eosinophilia, IL-5 exposure, or both, this downmodulation was not sufficient to impair in vitro killing by NK cells in the presence of afucosylated anti-EMR1 antibody. More importantly, administration of a single dose of afucosylated chimeric anti-EMR1 antibody induced rapid and sustained depletion of peripheral blood eosinophils without effect on other peripheral blood cells or evidence of clinical toxicity. Although the number of animals studied was small, these findings suggest that selectively targeting eosinophils using a Humaneered afucosylated anti-EMR1 antibody might provide a safe and effective strategy for the treatment of eosinophilic disorders.
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Clinical implications: Afucosylated antibody to the human eosinophil-specific surface receptor EMR1 shows promise as a new therapy for eosinophilic disorders.
METHODS
Detection of surface EMR1 by means of flow cytometry
EMR1 expression in bone marrow aspirates and peripheral blood was assessed by means of multiparameter flow cytometry with directly conjugated antibodies against CD45 (clone 2D1), CD34 (clone 8G12), IL-5Ra (CDw125; clone A14), CD16 (clone 3G8), CD9 (M-L13), CD14 (M5E2), CD49d (clone 9F10), CD117 (clone 104D2), CD19 (SJ25C1), CD15 (HI98), CD3 (SK7), CD69 (FN50) (BD Biosciences), CD203 (97A6) (Beckman Coulter, Indianapolis, Ind), CD10 (MEM78) and CD64 (10.1) (Invitrogen), Siglec-8 (7C9; BioLegend, San Diego, Calif), and anti-EMR1 (clone 1E7; Kalobios Pharmaceuticals, South San Francisco, Calif). After antibody staining, red blood cells were lysed and samples were fixed, as previously described.
E1
Eosinophils were identified in whole blood as CD45 
Primers used for real-time quantitiative PCR
EMR1 and Siglec-8 mRNA were amplified by using previously published primer sets E2,E3 and 1X SYBR Green (SA Biosciences, Frederick, Md) in a final 20-mL reaction volume. Forward and reverse primer sequences for the 18S control were 39-GCCCGAAGCGTTTACTTTGA-59 and 39-TCCAT TATTCCTAGCTGCGGTATC-59, respectively. The cationic proteins MBP, EPX, ECP, EDN, and IL5RA (membrane form) were amplified by using the following commercially available TaqMan primers (Applied Biosystems) in a final volume of 10 mL, according to the manufacturer's instructions: MBP, PRG2, Hs00794928_m1; EPX, Hs00946094_m1; ECP, RNAse2, Hs00795553_s1; EDN, RNAse3, Hs00795553_s1; IL-5RA, s00602482_m1; and 18S, X03205.1.
Immunostaining
Immunohistochemical staining for EPX was performed on formalin-fixed paraffin sections of a skin biopsy specimen by using a mouse anti-mouse mAb (1:500, provided by Dr J. J. Lee), as previously described. E4 Slides were deparaffinized, and heat-induced epitope retrieval was accomplished with Leica retrieval solution (citric buffer) for 25 minutes. Immunostaining for EMR1 was performed on an adjacent frozen sample of the same biopsy specimen with mouse 1E7 antibody at 10 mg/mL. Slides were prepared by Histoserv (Germantown, Md). Anti-EPX and anti-EMR1 antibodies were detected with the BondMax biotin-avidin free polymer-based detection system, with diaminobenzidine as the chromogen. Samples were analyzed on a Leica BondMax autostainer (Leica Microsystems, Bannockburn, Ill).
Immunofluorescence staining for EMR1, EPX, and CD68 was performed on acetone-fixed nasal polyp frozen sections. Slides were washed twice with PBS with 0.1% Tween 20 (PBST) before incubation with 700 mL of blocking solution (2% BSA, 1.5% goat serum [Abcam] , and 1.5% donkey serum [Abcam] in PBS) at room temperature for 1 hour. After 3 washes with PBS, slides were incubated overnight at 48C with mouse 1E7-Alexa Fluor 595 (10 mg/mL), mouse anti-EPX antibody (diluted 1:200 with 2% BSA with PBS, Abcam), and/or mouse anti-CD68 (clone KP-1, diluted 1:2; Ventana). The slides treated with anti-EMR1, anti-EPX, and anti-CD68 were then washed and incubated with goat anti-mouse IgG-DyLight 488 (Jackson ImmunoResearch, West Grove, Pa) at 3 mg/mL in 2% BSA with PBS at room temperature for 1 hour. After 3 washes with PBST, 2 to 3 drops of mounting medium (VECTASHIELD Mounting Medium; Vector Laboratories, Burlingame, Calif) were added before cover slipping. Images were taken on a Nikon fluorescent microscope (Nikon, Tokyo, Japan).
c1E7 ELISA
Plasma samples were analyzed for c1E7 by using an antigen-based ELISA. Briefly, a microplate was coated with 100 ng per well of EMR1-Fc (KaloBios Pharmaceuticals) in coating buffer (20 mmol/LTris and 150 mmol/L NaCl, pH 8.0). After incubation for 1 hour at 378C with shaking, the plate was washed 3 times with wash buffer (PBST) and blocked for 20 minutes at 378C with Superblock (Pierce, Rockford, Ill). Diluted cynomolgus monkey plasma samples (1:300 and/or 1:600 for group 1 and 1:1500 and/or 1:3000 for group 2) and recombinant standards were incubated for 1 hour at room temperature. The plate was washed 3 times with wash buffer before addition of peroxidaseconjugated AffiniPure goat anti-human IgG Fab-specific antibody (10 ng/mL in PBST with 1% BSA, Jackson ImmunoResearch). After a final wash step, TMB substrate solution was added (Invitrogen), and the reaction was allowed to proceed for 7 minutes before the addition of stop solution (1N H 2 SO 4 ) . Absorbance was read at 450 nm with a Thermomax Molecular Device microplate reader. Data were plotted and fitted by using a 4-paramter logistic regression with SoftMax Pro 4.0 software (Molecular Devices, Sunnyvale, Calif). The concentration in plasma samples was determined based on the values from the standard curve.
Measurement of eosinophil granule proteins
Levels of eosinophil granule proteins (MBP, ECP, EDN, and EPO) were measured in supernatants and primate plasma by using a customized suspension array assay in multiplex (Makiya et al, unpublished data). Coupling of antibodies to the microspheres and assay conditions were performed according to the manufacturer's instructions (Luminex, Austin, Tex). Briefly, supernatants and plasma were reduced and alkylated to remove MBP from complexes E5 before incubation at a final dilution of 1:8.8 (supernatants) or 1:44 (plasma) with magnetic microspheres coupled to mouse anti-MBP, anti-ECP, anti-EDN, and anti-EPO mAbs. E6 The microspheres were subsequently incubated with rabbit anti-MBP, anti-ECP, anti-EDN, and anti-EPO E6 and biotinylated goat anti-rabbit IgG and PE-streptavidin (Jackson ImmunoResearch) and analyzed with a Bio-Plex 200 (Bio-Rad Laboratories, Hercules, Calif) instrument. All assays were performed in duplicate, and concentrations were calculated based on a standard curve with SoftMax Pro Software (Molecular Devices). and CD69 on purified eosinophils after 2 hours of stimulation (n 5 14, 6 healthy donors and 8 patients with HES). C, EMR1 mRNA upregulation by IL-5 after 6 hours of stimulation (n 5 13, 4 healthy donors and 9 patients with HES). CM, Culture medium; Dmfi, change in mean fluorescence intensity. *P < .05, **P < .01, and ***P < .001. 
